Heatwurx Inc.

PCSA Healthcare Biotechnology

In the quarter to June 2026, EPS grew 81.0% and free cash flow grew 20.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

1.79 0.07 −3.76%
Market cap
$5.2M
P/E
1.8×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
−251.45
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
0.87 0.98 2.54 3.76
Net Debt/EBITDA
0.08 0.51 1.50 1.81
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.66) (1.56) (2.87) (1.83)
Book value per Share
(0.12) 0.97 4.26 3.07
Free Cash Flow
(1.81) (4.09) (3.75) (3.48)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates